234 related articles for article (PubMed ID: 16266903)
1. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
[TBL] [Abstract][Full Text] [Related]
2. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients.
López-Pedrera C; Jardí M; del Mar Malagón M; Inglés-Esteve J; Dorado G; Torres A; Félez J; Velasco F
Thromb Haemost; 1997 Jan; 77(1):62-70. PubMed ID: 9031451
[TBL] [Abstract][Full Text] [Related]
5. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Mustjoki S; Alitalo R; Stephens RW; Vaheri A
Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Zhang XH; Hu Y; Bao L; Jiang Q; Yang LH; Lu XJ; Hong M; Xia LH; Guo T; Shen GX; Zhu HH; Zhao T; Song SJ
Chin Med J (Engl); 2009 Sep; 122(17):1969-73. PubMed ID: 19781379
[TBL] [Abstract][Full Text] [Related]
7. Membrane and intracellular platelet-activating factor receptor expression in leukemic blasts of patients with acute myeloid and lymphoid leukemia.
Donnard M; Guglielmi L; Turlure P; Piguet C; Couraud MJ; Bordessoule D; Denizot Y
Stem Cells; 2002; 20(5):394-401. PubMed ID: 12351810
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
Castagnari B; Moretti S; Latorraca A; Rigolin GM; Balsamo R; Lanza F; Castoldi GL
Boll Soc Ital Biol Sper; 1995; 71(5-6):141-7. PubMed ID: 8519488
[TBL] [Abstract][Full Text] [Related]
10. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of acute myeloid leukemia and system Coulter VCS.
Bruno A; Del Poeta G; Venditti A; Stasi R; Adorno G; Aronica G; Suppo G; Di Rienzo AM; Iazzoni R; Tribalto M
Haematologica; 1994; 79(5):420-8. PubMed ID: 7843628
[TBL] [Abstract][Full Text] [Related]
12. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
14. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
15. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
Berdel WE; Kulimova E; Kolkmeyer A; Zühlsdorf M; Serve H; Büchner T; Oelmann E
Ann Hematol; 2005 Nov; 84(12):771-3. PubMed ID: 16094532
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
18. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
